Sophia Abene

Multicenter study will measure efficacy, safety, and immunogenicity in adults 18–59 across Europe.

Environmental modeling shows inpatient IV therapy has the highest carbon, water, and waste footprint, while OPAT offers major reductions.

Episode 2, Part 4, Robert Bransfield, MD, connects neural circuits, inflammatory responses to infection, and impulsivity in violent behavior.

Georges C.Benjamin, MD, executive director of the American Public Health Association, details practical implications for clinical teams.

Part 2 on coverage across payers, evidence needs for COVID-19, hepatitis B, and MMRV, and clinician messaging for maternal and newborn protection.

In episode 2, part 3 of 4, Robert Bransfield, MD, explains how ecological change, zoonotic infections, and neurological impairments may contribute to violent behavior.

In part 1 of our conversation, the VP of the NFID discusses ACIP’s recent meeting, including COVID-19 shared decision-making, informed-consent debates, and new policy actions on hepatitis B and MMRV.

Insights from Jaya Aysola, MD, MPH, DTMH; and John C. Lin, MD candidate, on clinical workflows, social needs screening, and policy levers.

Merck’s single-dose, weight-independent antibody provides about five months of protection; EC decision pending, and it is already FDA approved in the United States.

ACIP keeps broad access to COVID-19 vaccines, requests stronger informed-consent materials, and does not require prescriptions.

Today’s MMWR recommends twice-yearly subcutaneous lenacapavir for people ≥35 kg, citing PURPOSE-1/2 efficacy, a favorable safety profile with mostly mild to moderate injection-site reactions, and potential adherence benefits.

Eloise Williams, MBBS, BMedSci, MPHTM, FRACP, FRCPA, details how an 8-criterion genomics-plus-clinical framework narrowed 5,881 isolates to 5 strains while prioritizing safety and contemporary relevance.

TNX-4800 targets OspA to block Borrelia transmission; positive phase 1 data reported and an adaptive phase 2/3 study is planned.

Vincent Lo Re, MD, MSCE, FISPE, reviews HR-pQCT findings, IL-18 and TNF-α declines, and guidance for clinicians.

Catherine M. Stein, Evelyn Griffin, Hilary Blackburn, Kirk Milhoan, and Raymond Pollak join ACIP as the panel prepares to vote on MMRV, hepatitis B, and COVID-19 recommendations following the June reconstitution.

Shin Hye Yoo, MD, PhD, on a nationwide cohort showing end-of-life antibiotic use clusters in the final months, is higher in hematologic cancers, and offers a window for stewardship and goal-concordant care.

Sean Tucker, PhD, discusses the immunogenicity readouts, why mucosal markers matter, and what’s next as the program moves toward phase 2b.

At the ICE-HBV Cure Symposium, EBT-107 showed reduced intrahepatic HBV DNA and no increase in chromosomal translocations, supporting a path toward first-in-human testing.

Democratic Republic of the Congo reports 28 suspected cases and 15 deaths, as Africa CDC and WHO mobilize vaccines, surveillance, and rapid response teams to contain the 16th Ebola outbreak since 1976.

This week, US measles totals reached 1,454, a 750-plus-day SARS-CoV-2 infection in a person with HIV informed care, implementation science efforts advanced access, and a universal flu adjuvant showed promise.

CDC’s recent ArboNET snapshot shows widespread human and non-human activity, preliminary totals subject to change, and no lineage reporting on the dashboard.

Record-high 127.1/100,000 hospitalizations with co-circulating influenza A strains and similar in-hospital severity to prior years.

Head-to-head phase 1 data indicate larger fecal IgA responses after a single tablet vs first-generation constructs, with plans to advance to mid-stage testing.

Oxford’s Prof Katrina Lythgoe and Mahan Ghafari, DPhil, report ONS-CIS data on 576 persistent UK infections with rapid within-host evolution and rare transmission after one month.

CDC reports 3 new cases this past week, bringing the 2025 total to 1,454 confirmed cases across 42 jurisdictions, with 37 outbreaks.

William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.

16 cases of Salmonella Enteritidis across 10 states, including seven hospitalizations, are under investigation; antimicrobial resistance may complicate treatment.

Cocrystal Pharma to launch phase 1b study by year-end 2025, targeting prevention and treatment of viral gastroenteritis caused by norovirus.

41 cases of nongroupable N meningitidis conjunctivitis were identified at Joint Base San Antonio-Lackland, highlighting diagnostic, treatment, and surveillance implications for congregate living settings.

From COVID-19 antivirals to RSV, influenza, malaria, and gram-negative infections, new research highlights both advances and ongoing challenges in infectious disease prevention and treatment.